79 results about "Glycated protein" patented technology

Multilayer reagent test strips for quantitating glycated protein in a fluid sample, as well as methods for using the same, are provided. The subject multilayer test strips include at least a filter layer, a proteinase layer and a ketoamine oxidase signal producing and fluid flow control system layer. In using the subject test strips, a fluid sample is applied to the test strip and a signal is generated that can be employed to quantitate the glycated protein level in the sample. The quantitated glycated protein level can then be employed to determine the amount of glycated protein in the fluid sample. Also provided are kits and systems that include the subject test strips and find use in practicing the subject methods. The subject compositions and methods find use in glycated protein monitoring applications, among other utilities.

The present invention relates to triazine compounds and their analogs and derivatives, and methods and compositions comprising these compounds. The compounds and compositions of this invention are useful for, among other things, treating pathophysiological conditions arising from inflammatory responses, inhibiting or blocking glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells, inhibiting smooth muscle proliferation, treating vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis, and the like.

PCT No. PCT / JP98 / 01904 Sec. 371 Date Aug. 13, 1999 Sec. 102(e) Date Aug. 13, 1999 PCT Filed Apr. 24, 1998 PCT Pub. No. WO98 / 48043 PCT Pub. Date Oct. 29, 1998A sample containing a glycated protein is treated with Protease XIV or a protease from Aspergillus genus, thereafter (or while treating the sample with the above protease) FAOD (fructosyl amino acid oxidase) is caused to react with the sample so as to measure the amount of oxygen consumed by the FAOD reaction or the amount of the resultant reaction product, thereby to measure the glycated protein. According to the above method, the glycated protein can be fragmented while the decomposition of the FAOD itself is prevented, thereby to facilitate the binding of the protein with the FAOD and to improve the sensitivity of the detection.

The present invention relates to a prokaryotic host cell comprising eukaryotic glycosyltransferase activity, where the eukaryotic glycosyltransferase activity is eukaryotic dolichyl-linked UDP-GlcNAc transferase activity and eukaryotic mannosyl-transferase activity. Also disclosed is a method of producing a glycosylated protein by providing a prokaryotic host cell comprising the eukaryotic glycosyltransferase activity and culturing the prokaryotic host cell under conditions effective to produce a glycosylated protein. Another aspect of the present invention pertains to a method for screening bacteria or bacteriophages by expressing one or more glycans on the surface of a bacteria, attaching a label on the one or more glycans on the surface of the bacteria or on the surface of a bacteriophage derived from the bacteria, and analyzing the label in a high-throughput format. A glycosylated antibody comprising an Fv portion which recognizes and binds to a native antigen and an Fc portion which is glycosylated at a conserved asparagine residue is also disclosed.

Based on a principle that is different to that of a conventional enzymatic method, the present invention provides a novel method for assaying a glycated protein by a simple procedure, within a short period of time, and with high accuracy, and a reagent kit for assaying used in the method. The method for assaying a glycated protein in a sample is realized by treating a glycated protein-containing sample with protease to liberate a glycated peptide, preferably an α-glycated peptide, particularly preferably an α-glycated dipeptide, from a glycated protein, allowing an oxidase to react with the liberated glycated peptide, and determining the produced hydrogen peroxide.

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Compositions for accurately assaying a glycated protein by: 1) avoiding effects of globulin and ascorbic acid components, 2) siabilizing proteases and at least enzymes acting on glycated amino acids; 3) accurately assaying albumin; and 4) assaying glycated albumin while avoiding the effects of glycated hemoglobin, and an assay method are provided. Thus, the contents of a glycated protein and glycated albumin can be more accurately determined.

Compounds of formula (I), and methods and / or compositions comprising compounds that are effective in modulating inflammatory responses, such as those resulting from AGE and glycated protein accumulation are provided. Methods and / or compositions comprising compounds that are effective in modulating smooth muscle cell proliferation and the diseases or conditions related thereto are also provided.

Disclosed relates to an electrochemical determination system of glycated proteins, the system comprising: a filtering means for filtering labeled compounds bound to glycated proteins and non-glycated proteins after adding labeling compounds, capable of selectively binding to the glycated proteins to a solution, in which glycated / non-glycated proteins coexist, to be bound all to the glycated proteins; and a quantifying means for quantifying the filtered labeling compounds, not bound to the glycated proteins. The system of the present invention filters the residual labeled compounds left after binding to glycated proteins to quantify, instead of directly quantifying glycated proteins via the known glycated protein determination methods, thus simplifying the configuration of the system that can provide exact determinations with a low cost. Moreover, the electrochemical determination system of glycated proteins of the present invention minimizes the interference that the proteins are absorbed to an analysis device and a sensor in the system, not using immune antibodies that are expensive and have limited lives and, furthermore, not modifying the electrodes of the electrode sensor with antibodies or enzymes, thus facilitating mass production, quality control and circulation of the products.

The present invention provides a convenient, efficient method for assaying glycated protein, fructosyl peptide, or fructosyl amino acid which can be performed with reduced effect of fructosyl lysine compounds. The invention also provides a reagent for the assay.The invention is directed to a method for reducing the effect of a fructosyl lysine compound in an assay of fructosyl peptide or fructosyl amino acid contained in a sample, characterized by including causing an enzyme for assaying fructosyl peptide or fructosyl amino acid to act specifically on fructosyl peptide or fructosyl amino acid at a pH of 4.0 to 7.0 and measuring the product at a pH of 4.0 to 7.0; and a method for assaying glycated protein through the above method.

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

This invention relates generally to the field of glycated protein detection. In particular, the invention provides chimeric proteins, nucleic acids encoding the chimeric proteins, methods and kits for assaying for a glycated protein in a sample, using inter alia, an amadoriase.

The present invention provides an electrochemical detection method for content of glycosylated hemoglobin in the blood, and is characterized in that: whole blood specimen is diluted by combined liquid ranging from 30 times to 70 times and passes through a glycosylated protein recognizer, electric activated small molecules are filled into the effluent liquid from the glycosylated protein recognizer, and electrochemical response of the liquid is detected by chemically modified electrodes after the filling, thereby obtaining the concentration of the blood glucose. The glycosylated protein recognizer is eluted by elute solvent, and the electrochemical response of the elute solvent is detected and the concentration of the glycosylated hemoglobin is obtained, thereby obtaining the content of the glycosylated hemoglobin of the sample after calculation. As the electrochemical detection is simple in operation, lower in cost and rapid in the analysis, the present invention is expected to realize the rapid determination of the clinical glycosylated hemoglobin and the rapid determination of the glycosylated hemoglobin after separation and elution.

The present invention relates to a method for producing α-glycated dipeptide, which comprises causing protease to act on N-terminal-glycated peptide or N-terminal-glycated protein. The present invention further relates to a method for determining the amount of α-glycated dipeptide, which comprises causing a fructosyl peptide oxidase to act on the α-glycated dipeptide obtained by the above method and then determining the amount of the thus generated hydrogen peroxide. According to the present invention, a method for producing α-glycated dipeptide is provided, which enables the simple, rapid, and efficient production of α-glycated dipeptide from glycated protein or glycated peptide. Furthermore, according to the present invention, a method for determining the amount of α-glycated dipeptide is provided, which enables to determine the amount of α-glycated dipeptide in a highly precise manner within a short time period.

A method of producing a protein degradation product is provided, by which a protein (including a peptide) in a sample can be degraded quickly and efficiently. A sample containing a protein is treated with a protease in the presence of the tetrazolium compound to give a protein degradation product. Further, by causing a redox reaction between the glycation site of a glycated protein degradation product obtained by this method and a fructosyl amino acid oxidase, and then determining this redox reaction, it is possible to determine the amount of a glycated protein quickly. As the tetrazolium compound, 2-(4-iodophenyl)-3-(2,4-dinitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium salt etc. can be used.

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

A cartridge for measuring a concentration of a glycated protein in a wide measurement range, a system for measuring a glycated protein, and a method of measuring a glycated protein using same.

The invention involves methods, compositions, and kits for detecting glycated proteins in a sample (e.g., urine or other bodily fluid) from a subject. Also provided are methods, compositions, and kits for diagnosing or following a diabetic condition of the subject or screening for a diabetic condition in a population of subjects based upon the detection of the glycated protein(s) in the sample.

Disclosed is a mutant fructosyl amino acid oxidase modified at an amino acid residue involved in proton relay system. The mutant fructosyl amino acid oxidase has reduced oxidase activity while substantially maintaining its dehydrogenase activity. The invention also provides an assay device and assay method for measuring glycated protein.

The invention discloses a preparation method of a composition with anti-glycation and anti-skin-aging effects in the technical field of skin care product composition preparation. The composition withthe anti-glycation and anti-skin-aging effects comprises a phase A and a phase B, wherein the phase A is prepared from 0.1 part of sclerotium rolfssii gum, 2 parts of 1,3butanediol, 1 part of glyceroland 87.75 parts of water, the phase B is prepared from 5 parts of malus domestica fruit cell culture extracts, 2 parts of glycosylglycerol, 5 parts of water, 5 parts of nicotinamide, 5 parts of glycerol, 5 parts of caprylyl glycol, 5 parts of xanthan gum and 5 parts of salvia miltiorrhiza extracts. the skin effectively recovers the young state; the glycated protein is eliminated; the formed crosslinking Maillard reaction collagen is broken; the skin color unevenness and yellow color phenomena can be reduced; the composition can be used for mask essence liquid, and can also be used for essenceliquid and emulsion cream.

A method for measuring a glycated protein, a glycated peptide, or a glycated amino acid is provided. In this method, proteolytic activity of the protease is controlled to thereby realize high accuracy of the measurement. Also provided is a reagent used in such a measurement. More specifically, this invention provides a method of measuring a glycated protein, a glycated peptide, or a glycated amino acid comprising the steps of treating a sample containing the glycated protein with a protease for releasing a glycated peptide or a glycated amino acid; reacting the released glycated peptide or glycated amino acid with corresponding oxidase for generation of hydrogen peroxide; and measuring the resulting hydrogen peroxide with peroxidase and an oxidizable color developing reagent; wherein reaction solution before the reaction with the oxidase is adjusted to a pH of 1 to 5; and a reagent used in such measurement.

The present invention provides a method of measuring a glycated protein in a sample using a redox reaction, by which the glycated protein can be measured accurately with high sensitivity. In order to remove a glycated amino acid present in the sample other than the glycated protein, the glycated amino acid is degraded in advance by causing a fructosyl amino acid oxidase to act thereon, and thereafter, a fructosyl amino acid oxidase is caused to act on the glycated protein in the presence of a tetrazolium compound and sodium azide to cause a redox reaction. The amount of the glycated protein is determined by measuring the redox reaction. As the glycated protein, glycated hemoglobin is preferable.

The present invention relates to the field of immunology, in particular allergenicity. More specifically it relates to the reduction of allergenicity by the in vivo N-glycosylation of proteins.